These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13389581)

  • 1. [Comparative study on daily changes of glycemia produced by the three most recent types of depot insulin; NPH, zinc-insulin and long insulin].
    BENAZZO L; MARIGO S
    Prog Med (Napoli); 1956 Oct; 12(20):622-7. PubMed ID: 13389581
    [No Abstract]   [Full Text] [Related]  

  • 2. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of insulin NPH formulations.
    Norrman M; Hubálek F; Schluckebier G
    Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of insulin glargine in primary care practices in Germany.
    Rathmann W; Haastert B; Riebel P; Schroeder-Bernhardi D; Kostev K; Huppertz E; Giani G
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):252-6. PubMed ID: 17479442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
    Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C; Jung R; Hofmann U
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical studies on new insulin preparations with prolonged action; one daily injection with insulin zinc preparations].
    HALLAS-MØLLER K; JERSILD M; PETERSEN K; SCHLICHTKRULL J
    Ugeskr Laeger; 1951 Dec; 113(52):1767-71. PubMed ID: 14931627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.